IN CONTRAST to prolonged oxygen deprivation, which can lead to endothelial cell death (17, 18, 37) , moderate and transient hypoxic conditions may elicit pro-survival or even proliferative responses in these cells. These pro-survival effects can be either due to hypoxia-induced activation of signaling processes endogenous to the endothelial cells or to paracrine factors produced by adjacent cells (19, 28, 34) . As an example of a pro-survival response, we described previously that transient hypoxia induces a proliferative response of endothelial cells, caused by endogenous signaling and not by paracrine factors (34) . This proliferative response is triggered by hypoxia-induced activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway in endothelial cells and is independent from vascular endothelial growth factor (VEGF) (33) . In many tissues, hypoxia also upregulates expression of VEGF in a hypoxia-inducible factor (HIF)-dependent manner, and this in turn can stimulate endothelial growth in a paracrine fashion (3, 23, 29) . It is assumed that these endogenous and paracrine effects act together in favor of hypoxia-induced angiogenesis and spontaneous revascularization of malperfused tissue (24) .
In the present study we investigated whether transient hypoxia can also activate another endogenous pro-survival mechanism in endothelial cells, i.e., an endogenous anti-apoptotic response. Endothelial survival results from a delicate balance between pro-and anti-apoptotic stimuli. Several pro-apoptotic stimuli that act on endothelial cells in inflammation or severe ischemia trigger apoptosis via activation of the Bcl-2 family member Bad (9, 27) . Bad can promote apoptosis by permeabilization of the mitochondrial membrane leading to dissipation of mitochondrial membrane potential facilitating the release of cytochrome c, which finally promotes activation of effector caspases (4, 30) . Bad can be inhibited by its phosphorylation. The pro-survival pathways phosphatidylinositol 3-kinase (PI3K)/Akt and MEK/ERK target Ser136 and Ser112 at specific phosphorylation sites of Bad, respectively (7, 12, 35) . As a consequence, the process of apoptotic cell death is impeded (43) .
In the present study, the pro-survival effects of transient hypoxia were analyzed in cultures of endothelial cells. Three different types of endothelial cells were compared (human umbilical vein, pig aorta, and from rat coronary microvasculature). The cells were exposed to the robust pro-apoptotic challenge of serum deprivation (2, 44) , and it was then investigated whether transient hypoxia can inhibit the apoptotic process. The role of PI3K/Akt and MEK/ERK signaling pathways toward the pro-apoptotic molecule Bad and caspase 3 were analyzed.
MATERIALS AND METHODS

Materials.
Horseradish peroxidase (HRP)-conjugated anti-mouse and -rabbit IgG antibodies were purchased from Amersham Biosciences (Freiburg, Germany); Annexin V-FITC-Apoptosis detection kit and FITC-bromodeoxyuridine (BrdU)-Flow kit were from BD Biosciences (Heidelberg, Germany); anti-␣-tubulin antibodies, PD98059, and UO126 were obtained from Calbiochem (Darmstadt, Germany); antiAkt, anti-phosphospecific Akt (Ser473), and anti-phosphospecific Bad (Ser112) antibodies were from Cell Signaling Technology (Danvers, MA); anti-goat IgG HRP-conjugated donkey antibodies were from Dianova (Hamburg, Germany); phosphorothioated antisense and non-sense oligonucleotides were obtained from Invitrogen (Karlsruhe, Germany); JC-1 was from Molecular Probes (Eugene, OR); enhanced chemiluminescence kit was from Pierce (Bonn, Germany); endothelial cell basal medium plus supplement pack were from PromoCell (Heidelberg, Germany); anti-caspase 3 active antibodies were from R&D Systems (Minneapolis, MN); Complete was from Roche (Mannheim, Germany); anti-Bad, anti-phosphospecific Bad (Ser136), and anti-ERK 2 antibodies were from Santa Cruz Biotechnologies (Heidelberg, Germany); anti-vinculin and anti-rabbit IgG FITC-conjugated antibodies and CCCP were from Sigma (Steinheim, Germany). All other chemicals were of the best available quality, usually analytical grade.
Cell culture. The investigation conforms to the "Guide for the Care and Use of Laboratory Animals" published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996) and the principles outlined in the Declaration of Helsinki (Cardiovasc Res 35: 2-3, 1997). Macrovascular endothelial cells from human umbilical veins (HUVEC), porcine aorta (PAEC), and microvascular coronary endothelial cells from 250-g Wistar rats (RCEC) were isolated and cultured according to Peters et al. (31) in a fully humidified atmosphere at 37°C and 5% CO 2. Confluent cultures of primary endothelial cells were trypsinized in phosphate-buffered saline [PBS, composition in mM: 137 NaCl, 2.7 KCl, 1.5 KH 2PO4, and 8.0 Na2HPO4, at pH 7.4, supplemented with 0.05% (wt/vol) trypsin, and 0.02% (wt/vol) EDTA] and seeded at a density of 2.2 ϫ 10 4 cells/cm 2 on 35-or 100-mm culture dishes or 25-mm round glass coverslips for immunocytochemistry. Experiments were performed 2 to 3 days after seeding, with a confluence of ϳ70% to 100%.
HUVEC were cultured in PromoCell endothelial cell basal medium supplemented with 10% (vol/vol) fetal calf serum (FCS), 0.4% (vol/ vol) endothelial growth supplement with heparin, 0.1 ng/ml human epidermal growth factor (EGF), 1.0 g/ml hydrocortisone, 1 ng/ml human basic fibroblast growth factor (bFGF), 100 IU/ml penicillin G, and 100 g/ml streptomycin. PAEC and RCEC were cultured in cell basal medium 199 with Earle's salt, supplemented with 100 IU/ml penicillin G, 100 g/ml streptomycin, and 20% (vol/vol) newborn calf serum (NCS) or 10% (vol/vol) NCS and 10% (vol/vol) FCS, respectively.
Experimental protocols. Deprivation from serum and oxygen are major determinants of an ischemic environment. To emulate this condition, serum was removed by washing with PBS and cells were incubated in serum-free endothelial cell basal medium (37°C, 5% CO2) for 24 h as a pro-apoptotic challenge. To identify the optimal time for transient hypoxia, in a set of experiments cells were exposed to 0.5, 1, 2, and 3 h of hypoxia (PO2 Ͻ 10 mmHg) or control normoxia (PO2 ϭ 140 mmHg) in gas-tight chambers, under a constant stream of humidified N2 or air, respectively. Incubation was performed in modified Tyrode solution (composition in mM: 150 NaCl, 2.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 1.0 CaCl2, and 30.0 N-2-hydroxyethylpiperazine-N=-2-ethanesulfonic acid; pH 7.4, 37°C), and PO2 was monitored by a polarographic oxygen sensor. Cell viability was determined after 24 h of incubation in serum-free culture medium by fluorescent-activated cell sorting (FACS). Highest cell survival was observed after 2 h of hypoxia. Therefore, in the present study all further experiments were performed at 2 h hypoxia. Inhibitor stock solution of PD98059 and UO126 were prepared with dimethylsulfoxide (DMSO) and applied 30 min before hypoxic or normoxic treatment. Final solvent concentrations were Ͻ0.1% (vol/vol). Same final concentrations of DMSO were also included in all respective control experiments.
Cell proliferation analysis. Cell proliferation was examined by determination of cell number and incorporation of BrdU. After hypoxia, cultures were postincubated in serum-free medium under normoxic conditions for 24 h in the presence of 10 M BrdU either for the whole reoxygenation period or pulse labeled for 2 h from time point 2-4 h, 10 -12 h, and 22-24 h after hypoxia. As a positive control untreated proliferating cells were pulse labeled for 2 h or continuously for 24 h. Thereafter, cells were trypsinized, fixed, and immunostained with BrdU detection kit according to manufacturer's instructions. BrdU-positive cells were detected by FACS analysis.
Analysis of cell apoptosis. Apoptosis and necrosis was determined by FACS by using an Annexin V-FITC and propidium iodide (PI) staining according to manufacturer's instructions. Annexin V and PI were added to trypsinized endothelial cells, and samples of 10.000 cells were analyzed by flow cytometry on a FACS Calibur using CellQuest Pro software according to manufacturer's instruction. Cells that were Annexin-FITC positive and PI negative (early apoptosis) or positive for both (late apoptosis) were identified as apoptotic, whereas cells that were Annexin-FITC negative and PI positive were identified as necrotic, and nonstained cells were identified as vital.
Antisense experiments. Endothelial cells were transiently transfected with antisense phosphorothioate-modified (small letters) oligonucleotides to downregulate ERK 1/2. Endothelial monolayers were transfected with Fugene according to manufacturer's instructions with different concentrations of ERK 1/2 antisense (AS): 5=-GccgcCGCCGCCgccaT-3=; or scrambled non-sense (NS): 5=-CgcgcGCTCGCGcaccC-3= oligonucleotides 24 h before experiments. Highest effects of ERK 1/2 reduction was achieved with 500 nM AS, whereas NS had no effect. Therefore, in the present study all further experiments were performed with 500 nM ERK 1/2 AS or NS oligonucleotides.
Western blot analysis and ERK 2 activation. Detection of ERK 2 activation and standard Western blot analysis were performed as previously described (16) . To determine ERK 2 phosphorylation, proteins were separated by 12.5% SDS-PAGE with a 1:100 bisacrylamide/acrylamide ratio. By this method ERK 2 is separated into the phosphorylated and the nonphosphorylated protein, the latter of which migrates more rapidly. ERK 2 phosphorylation is given as percentage of total ERK 2. Activation of caspase 3 was determined by detection of the cleavage products. Primary antibody concentrations were as follows: anti-Akt, anti-AktϳP, anti-Bad, and anti-caspase 3 were 1:1,000, anti BadϳP 1:500, and anti-ERK 2 1:2,000, as recommended in either 4% (wt/vol) nonfat dry milk or 3% (wt/vol) BSA in PBS. Immunoreactivity was detected with enhanced chemiluminescence and quantified by densitometric analysis by using Quantity One software of ChemiDoc XRS (Bio-Rad). Immunoreactivity for all proteins evaluated was linear. In standard Western blot analysis the values were normalized against signals obtained either with respective to total protein, tubulin, or vinculin. Percent change in density was calculated by taking the normalized value of signal in control lane as 100%.
Immunocytochemistry. Activation of caspase 3 was also determined by immunocytochemistry. HUVEC grown on glass coverslips were treated as described, fixed with 4% (wt/vol) paraformaldehyde in PBS for 20 min at room temperature, and washed afterward with PBS. After permeabilization with 0.1% (vol/vol) Triton X-100 for 8 min and being blocked with PBS containing 3% (wt/vol) BSA, anti-active caspase 3 antibodies [1:200 in PBS 3% (wt/vol) BSA] were incubated overnight at 4°C. After washing was completed, FITC-labeled secondary antibody [1:200 in PBS 3% (wt/vol) BSA] was applied for 1 h. After washing was completed, coverslips were mounted in PBSglycerol (1:1, vol/vol) and analyzed by confocal microscopy (Zeiss, LSM 510 Meta).
Mitochondrial membrane potential. Changes in mitochondrial membrane potential (⌬⌿ m) were analyzed by using the dye 5,5=,6,6=-tetrachloro-1,1=,3,3=-tetraethylbenzimidazolcarbocyanine iodide (JC-1) (10, 32) . Confluent endothelial monolayers cultured on round glass coverslips were starved for 24 h. Before the experiments the cells were incubated with JC-1 (7.7 M) in medium M199 at room temperature in the dark. After 40 min, extracellular JC-1 was removed by a medium change and incubation for 5 min before measurements were started. The coverslips were mounted in a perfusion chamber of a fluorescence microscope (IX 70; Olympus, Hamburg, Germany) and superfused through gas-tight steel capillaries with modified Tyrode solution as described above. ⌬⌿ m was analyzed by using a TILL Photonics (Martinsried, Germany) imaging system. The excitation wavelength was 490 nm, and emitted light was detected at 530 and 580 nm corresponding to the peak emissions of the monomer (green fluorescence) and aggregate forms (orange fluorescence) of JC-1, Fig. 3 . Influence of transient hypoxia on apoptotic cell death induced by serum deprivation. HUVEC cultured in serum-free medium were exposed to hypoxia (H; solid bars) for 2 h and reoxygenated for 24 h. Controls were simultaneously incubated under normoxic conditions (N; open bars). A: percentage of vital and apoptotic cells 24 h after hypoxic or normoxic treatment are depicted. B: immunostaining of active caspase 3 using an anti-active caspase 3-specific antibody as an apoptotic marker. HUVEC were grown on coverslips in presence (ϩFCS) or absence of serum (ϪFCS) for 24 h. Cells were fixed before (ϪFCS; top) and after exposure to either normoxia or hypoxia for 2 h (bottom). Data are means Ϯ SD of n ϭ 9 separate experiments of independent cell preparations. *P Ͻ 0.05 vs. normoxic control. Transient hypoxia significantly reduced apoptosis and increased the number of vital cells. Accordingly, transient hypoxia reduced activation of caspase 3. respectively. Deenergizing conditions applied decrease the aggregate emission and increase the monomer emission. The fluorescence intensities detected were used to calculate the 580/530 nm emission ratio. After an equilibration period of 10 min, cells were exposed to hypoxia. After 2 h of hypoxia, 25 M carbonyl cyanide mchlorophenylhydrazone (CCCP) was added to completely uncouple mitochondria in endothelial cells. The effect of PD98059 (10 M) on ⌬⌿ m was analyzed at the onset of experiment, during hypoxia, and after addition of CCCP.
Statistical analysis. Data are given as means Ϯ SD of n experiments by using independent cell preparations. Results of ⌬⌿ m analysis were expressed as means Ϯ SE. The comparison of means between groups was performed by one-way analysis of variance (ANOVA) followed by a Bonferroni post-hoc test. Changes of parameters within the same group were assayed by multiple ANOVA analysis. Probability (P) values of Ͻ0.05 were considered significant.
RESULTS
Transient hypoxia and cell death.
To test the survival effect of transient hypoxia, endothelial cells were challenged by the pro-apoptotic stimulus of serum deprivation. Subsequently, the challenged cells were exposed to either 2 h of hypoxia or 2 h of normoxia, as a control. As shown in Fig. 1 , transient hypoxia resulted in a significant reduction of cell loss, as determined after 24 h of reoxygenation. This was true for HUVEC, PAEC, as well as from RCEC, in which the hypoxia-induced reduction of cell loss amounted to 25 Ϯ 6%, 15 Ϯ 3%, and 12 Ϯ 3%, respectively.
To investigate whether proliferation contributes to the relative increase in cell number at the end of the 24-h pro-apoptotic challenge, incorporation of BrdU was analyzed by pulse labeling starting at different time points during 24 h of reoxygenation. As shown in Fig. 2A , BrdU incorporation was equal between cells exposed to transient hypoxia or normoxia, and it was only one-fifth compared with BrdU incorporation in cultures kept in serum containing media for 24 h. These data show that the higher number of cells found in hypoxic-treated cell cultures cannot be attributed to a difference in cell proliferation.
To analyze the relationship of apoptotic versus necrotic cell death in response to the pro-apoptotic challenge, double staining with Annexin V and PI was performed and analyzed by FACS (Fig. 3A) . When exposed to the pro-apoptotic challenge alone, HUVEC exhibited 48 Ϯ 5% vital cells, 36 Ϯ 4% apoptotic cells, and 15 Ϯ 5% necrotic cells; when the challenge was preceded by transient hypoxia, the respective results were 61 Ϯ 7% vital (vs. control with P Ͻ 0.05, n ϭ 9), 26 Ϯ 6% (vs. control with P Ͻ 0.05, n ϭ 9) apoptotic, and 12 Ϯ 3% (not signifcant) necrotic cells. Similar results were obtained for PAEC and RCEC. In PAEC, the pro-apoptotic challenge caused 22 Ϯ 3% apoptotic cells, which was reduced to 15 Ϯ 3% (vs. control with P Ͻ 0.05, n ϭ 9) after transient hypoxia, necrotic cells were 8 Ϯ 1% in either case. In RCEC, the pro-apoptotic challenge caused 26 Ϯ 3% apoptotic cells and 19 Ϯ 1% (vs. control with P Ͻ 0.05, n ϭ 9) after transient hypoxia, necrotic cells were 9 Ϯ 1% in either case. These data show that the higher number of cells found when the pro-apoptotic challenge was preceded by transient hypoxia is indeed due to a difference in apoptosis. Immunocytochemical analysis of caspase 3 activation is in line with this result, as it shows a reduction in caspase 3 activation in serum-deprived cultures (ϪFCS) exposed to hypoxia (Fig. 3B) .
Role of Akt, Bad, and ERK 2 for the anti-apoptotic effect of transient hypoxia.
To analyze whether PI3K/Akt signaling is involved in hypoxia-induced reduction of apoptosis, activation of Akt was analyzed during the 2-h period of transient hypoxia and normoxia (Fig. 4) . As indicated by phospho-specific antibodies against Ser473, Akt phosphorylation was low and stayed low under both conditions when compared with serumcontaining cell cultures, indicating that hypoxia had no influence on Akt phosphorylation.
In line with our findings, the Akt-specific inhibitory phosphorylation site of the pro-apoptotic molecule Bad at Ser136, was not altered during the hypoxic challenge (data not shown). However, phosphorylation at Ser112, specific for the MEK/ ERK pathway, was slightly reduced in serum-deprived cultures, but significantly increased by 62 Ϯ 8% above the level of normoxic controls 30 min after onset of hypoxia (Fig. 5A) . This hypoxia-induced increase in Bad phosphorylation was abolished in presence of 10 M PD98059, an inhibitor of the MEK/ERK 2 pathway (Fig. 5B) .
Accordingly, hypoxia induced a transient increase in ERK 2 phosphorylation indicating that ERK 2 is activated (Fig. 6A) . In normoxic controls, this increase was not observed. In the presence of 10 M PD98059 (Fig. 6B ) or UO126 (data not shown), two chemically unrelated selective inhibitors of the upstream kinase MEK 1/2, the hypoxia-induced ERK 2 activation was abolished.
Analysis of the cell numbers (Fig. 7A) revealed that inhibition of the MEK/ERK pathway by 10 M PD98059 abolished the hypoxia-induced reduction of cell loss. This result was verified by application of specific antisense oligonucleotides against ERK 1/2. The effectiveness of ERK 1/2 downregulation is depicted in Fig. 7B , showing a reduction of ERK 1/2 content at an average of 50% at a concentration of 500 nM. Scrambled non-sense oligonucleotides served as negative controls and showed no effect on ERK 1/2 content. Analysis of vital and apoptotic cells revealed that application of ERK 1/2 antisense oligonucleotides abolished the protective effect of hypoxia on cell survival (Fig. 8) . Under normoxic conditions non-sense oligonucleotide-treated control cells exhibited 45 Ϯ 5% vital and apoptotic cells, respectively, whereas hypoxic treatment resulted in an increase in vital cells to 57 Ϯ 3% and a decrease of apoptotic cells to 35 Ϯ 3%. In contrast, antisense oligonucleotide-treated HUVEC failed to respond to the hypoxic stimulus showing 42 Ϯ 6% vital and 46 Ϯ 3% apoptotic cells, whereas similar distributions of 45 Ϯ 3% vital and 46 Ϯ 2% apoptotic cells were obtained after hypoxic treatment.
Effect of hypoxia on caspase 3 activity. To analyze the influence of hypoxia on the pro-apoptotic challenge, caspase 3 activation, and the role of MEK/ERK pathway, the 17-and 19-kDa active-caspase 3 cleavage products were detected by Western blot analysis in the absence and presence of MEK inhibitor PD98059 (Fig. 9 ). In agreement with the above observed initiation of apoptosis and as demonstrated before by immunocytochemistry (Fig. 3B) , caspase 3 was found to be activated after serum deprivation of endothelial cells for 24 h (Fig. 9A) . However, the deprivation-induced caspase 3 activation was significantly diminished during 2 h of hypoxia. Analysis of caspase 3 activation revealed that 1 h after onset of hypoxia caspase 3 was already decreased by 40 Ϯ 10%. In contrast, inhibition of the MEK/ERK pathway with 10 M PD98059 abolished the hypoxia-induced reduction of caspase 3 activation (Fig. 9B) , moreover, it induced an increase of caspase 3 activation in both, normoxic and hypoxic-treated cells.
Effect of hypoxia on mitochondrial membrane potential. To analyze the effect of MEK/ERK inhibition on mitochondrial integrity, ⌬⌿ m was analyzed by using the ⌬⌿ m -indicator JC-1. To inhibit the MEK/ERK pathway, cells were preincubated in the presence of the MEK inhibitor PD98059 (10 M), a maneuver that does not affect ⌬⌿ m (Fig. 10) . Exposure of the cells to hypoxia for 2 h increased ⌬⌿ m , which was abolished in presence of the MEK inhibitor.
DISCUSSION
The hypothesis of the present study was that transient hypoxia can protect endothelial cells against apoptotic cell death by an endogenous survival mechanism. The major findings are the following. First, transient hypoxia exerts an antiapoptotic effect in endothelial cells. Second, this anti-apoptotic effect is conferred via activation of the MEK/ERK-dependent pathway, but not PI3K/Akt, leading to phosphorylation of pro-apoptotic Bad, an increase of mitochondrial membrane potential, and inhibition of caspase 3 activation. Third, this hypoxia-induced survival mechanism is found in endothelial cells of different origin and may, therefore, be an ubiquitous mechanism of endothelial protection.
First, it was examined whether the increased cell number of endothelial cells exposed to hypoxia was due to differences in cell proliferation. However, DNA synthesis, indicated by BrdU incorporation, was at the same low level in all serum-deprived cells, and no difference between hypoxia-and normoxiatreated cells could be detected. Thus cell proliferation does not contribute to increased cell number under the given experimental conditions. In line with this finding differential FACS analysis of cell death revealed that transient hypoxia reduced the amount of apoptotic cells. Therefore, these data show that the protective effect of hypoxia is entirely due to a reduction in apoptotic cell death. This was true for all three endothelial cell types investigated.
In the present study endothelial cells were challenged by augmented serum deprivation to shift the balance of survival and apoptosis in the direction of apoptosis. This is distinctly different from our previous studies where cell cycle arrest was achieved by moderate serum restriction (1, 33, 34) . Here, a maneuver was used to go beyond a cell cycle arrest and expose endothelial cells to a severe challenge that emulates in part pro-apoptotic conditions in the ischemic tissue.
It is well documented that the chosen pro-apoptotic challenge by growth factor deprivation causes apoptosis by inactivation of the pro-survival PI3-kinase/Akt pathway (5, 13) . Akt, a central anti-apoptotic signal transducer with pleiotropic downstream effects, can inhibit apoptosis through phosphorylation and inactivation of the pro-apoptotic Bcl-2 family member Bad (7) . Inactivation of this pathway under the proapoptotic challenge was also found here, as demonstrated by significant decrease of phosphorylation of Akt itself at Ser473. Transient hypoxia, however, did not act through this pathway. In fact, Akt itself as well as the Akt-specific phosphorylation site on Bad at Ser136 was unaltered during hypoxia. This indicated that the pro-survival effect of hypoxia must be mediated by another pathway.
The other pathway here investigated is the MEK/ERK. Phosphorylation of ERK 2, indicating its activation, occurred as a rapid but transient response to hypoxia. Accordingly, we and others (1, 21, 33, 36, 42) have previously demonstrated that MEK/ERK are transiently activated during onset of hypoxia. In this study we found, that pro-apoptotic Bad at its inhibitory phosphorylation site Ser112 (12, 35) was also transiently increased during hypoxia. Interestingly, the transient ERK 2 activation preceded in time this Bad inactivation. In line with that, inhibition of MEK 1/2, the upstream kinase of ERK 1/2, by PD98059 as well as UO126 (data not shown), abolished both the hypoxia-induced phosphorylation of ERK 2 and that of Bad at Ser112. Taken together, the results show that transient hypoxia induces inactivation of the pro-apoptotic molecule Bad in a MEK/ERK-dependent manner. A similar MEK/ ERK-depended Bad inactivation leading to cell survival have been documented in cortical neurons subjected to hypoxic or ischemic stress (15, 38) .
Cleavage of caspase 3, indicating its activation, was observed under the pro-apoptotic challenge (8) . This was reduced in response to transient hypoxia. The latter effect could be abolished by inhibition of the MEK/ERK pathway. That these changes in apoptotic signaling are causally related to the anti-apoptotic effect of transient hypoxia is demonstrated by the findings that the hypoxia-induced reduction in apoptotic cell numbers was abolished when the MEK/ERK pathway was either inhibited pharmacologically or by pretreatment with ERK 1/2 antisense oligonucleotides. Supportingly, we found that inhibition of the MEK/ERK pathway abolished the hypoxia-induced increase in ⌬⌿ m . It is well established that reduction or loss of ⌬⌿ m is usually associated with apoptotic processes (10, 14, 22) , whereas maneuvers preventing loss of ⌬⌿ m were shown to protect cells from apoptotic cell death (11, 20, 39) . In this context our findings suggest that hypoxiainduced MEK/ERK activation, leading to phosphorylation and inactivation of the pro-apoptotic molecule Bad, results in a protection of mitochondrial membrane integrity by increasing ⌬⌿ m . As a consequence caspase 3 activation is reduced and cell survival facilitated.
In summary, we have shown that moderate transient hypoxia can induce a pro-survival effect in endothelial cells. This protective mechanism is induced rapidly after onset of hypoxia in a MEK/ERK-dependent pathway targeting the pro-apoptotic Bcl-2 family member Bad. This pathway as well as its endogenous nature distinguished this effect from the pro-survival mechanism exerted by paracrine VEGF, known to be mediated via PI3K/Akt (13) . The endogenous anti-apoptotic effect is remarkably robust, because it can inhibit even the pro-apoptotic challenge of growth factor deprivation. It is far beyond the scope of the present study to exclude that the MEK/ERK signaling may induce other anti-apoptotic pathways or that other MEK/ERK-independent signaling elements contribute to the anti-apoptotic effect of transient hypoxia. However, the study leads to a number of interesting questions, e.g., whether this early response during hypoxia bridges the gap until other survival factors such as VEGF responses can take effect (26, 29) . One may also wonder whether a pharmacological activation of the MEK/ERK pathway could protect endothelial cells against the pro-apoptotic effects of ischemia and inflammation in vivo (6, 25, 40, 41) . 
